A phase I and pharmacokinetic study of NM-3 administered orally once or twice daily on five consecutive days and repeated weekly for six weeks every eight weeks in patients with advanced solid tumors

Trial Profile

A phase I and pharmacokinetic study of NM-3 administered orally once or twice daily on five consecutive days and repeated weekly for six weeks every eight weeks in patients with advanced solid tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 26 May 2015

At a glance

  • Drugs NM 3 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Genzyme Corporation; Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top